Korábbi változatok

• manual key word literature searches, SME awareness of studies (ACEP/EC)
• Monitoring new trials and reviews on the L*VE Epistemonikos platform and the Cochrane COVID-19 study register (COVID-NMA Initiative)

• SMEs review content, track in spreadsheet (ACEP/EC)

From COVID-NMA Initiative:

• For each new RCT record and publish key information in a trial network map  (COVID-NMA Initiative)  
• Undertake risk of bias assessment
• Extract data relating to pre-determine outcomes, create and publish forest plots of quantitative data as appropriate
• Undertake GRADE evidence profiles for all comparisons
• Update and maintain GRADE evidence profiles as more trials are published

(From Sara Loree: CDC and WHO are combining their COVID databases; OSF databased of COVID-19 intervention trials; WHO Librarian Reserve Corps)

We have determined that monitoring and searching the two sources above precludes the need for other individual database searches. (COVID-NMA Initiative)

Resources and tools for researchers considering and conducting
COVID-19 evidence syntheses (From COVID-END Synthesizing WG)

Rapid Cochrane review on anticoagulation in COVID-19 patients

L*VE/Epistemonikos search on antithrombotics; can send email when new study/review/guideline is published.

(from Sara Loree: OSF protocol for living evidence summary)

We have developed a tool for monitoring the preprint servers to identify changes to the data presented. (COVID-NMA Initiative)

Curated article, review every few weeks based on keywords and filters, with direct links to PDFs to speed content access (ACEP/EC).

Map of all RCTs for prevention and treatment of COVID-19 including vaccines and rehabilitation. (COVID-NMA Initiative)

3rd party reviews the studies and provides summary of key data in easily digestible format (ACEP/EC)

Standards for sharing  (ACEP/EC)

We have initiated communication with all trialists to try to ensure consistent approaches e.g. selection of outcomes, reduction of risk of bias, and to invite them to contribute missing data. We also aim to request individual participant data. (COVID-NMA Initiative)

Check all that apply

__Better source/input materials [Details: ]

__Common format/terminologies for managing/sharing data [Details: ]

__Other [Details:]

Check all that apply (COVID-NMA Initiative)

__Better source/input materials [Details: ]

_x_Common format/terminologies for managing/sharing data [Details: ]

__Other [Details:]

COVID-END Needs:

Use an online administrative interface for processing records (rather than Excel) and a more elegant front-end solution for displaying the inventory

_x_Better source/input materials [Details: ] Harvest from all high-yield, high-quality sources

_x_Common format/terminologies for managing/sharing data [Details: ] COVID-END taxonomy

_x_Consistency of outcomes [Details:]

_x_Engagement with primary researchers and upstream stakeholders [Details: When gaps in the best-available evidence related to the pandemic response are identified (e.g., a taxonomy category in the inventory has no high-quality evidence synthesis available) engaging researchers and research funders may help to set priorities for research needed to fill gaps)]

_x_Engagement with decision makers and other downstream stakeholders [Details:] Regulator interactions with government officials in many Canadian provinces and in many other countries

Check all that apply (COVID-NMA Initiative)

_x_Better source/input materials [Details: ]

__Common format/terminologies for managing/sharing data [Details: ]

_x_Consistency of outcomes [Details:]

_x_Engagement with primary researchers and upstream stakeholders [Details:]

_x_Engagement with decision makers and other downstream stakeholders [Details:]

__Other [Details:]

---

Check all that apply

__Better source/input materials [Details: ]

__Common format/terminologies for managing/sharing data [Details: ]

__Other [Details:]

From COVID-END

Identify published systematic and rapid reviews from trusted sources (including VA ESP Covid-19 Evidence Reviews and Cochrane) and present these in the COVID-END inventory; Add decision-relevant information to each document included in the inventory in order to support easier assessments of relevance, including:

flagging review search dates (to support assessments of how up-to-date the evidence is);

appraising and reporting quality using AMSTAR 1 tool (to provide information about the quality of each review);

identifying which reviews are living and which have a GRADE evidence profile; and

creating declarative titles for ease of understanding and applicability for policymaker end user.

The COVID-END Inventory aims to identify best current evidence in the four taxonomies, and to identify those reviews that are living, up to date, high quality and where there is a GRADE evidence profile. Inventory also provides link to the underlying reviews in addition to outputs described above.

COVID-END ... aims also to commission living systematic reviews to address high priority areas that may not have been sufficiently addressed by evidence synthesis researchers.

Further outputs include resources for researchers and guidelines developers that are proposing to conduct a systematic review or develop clinical practice guidelines – aimed at reducing inadvertent and inappropriate duplication of effort and increasing the quality of reviews and guidelines produced

---

Living comprehensive assessment of all RCTs that address prevention and treatment of COVID-19

Living evidence syntheses and network meta-analysis as appropriate.  (COVID-NMA Initiative)